HeyJaredBioPharma Dive
BioPharma Dive is a specialized industry news outlet focused on the global biopharmaceutical sector, with an emphasis on drug development, regulatory policy, and the business strategies shaping biotech and large pharmaceutical companies.
- Indexed articles, last 90 days
- 76
- Latest publication
- Oct 1, 2026
- Audience
- Top 1M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
BioPharma Dive Trendline on Radiopharmaceuticals (opens the original)
Read excerpt
More than a dozen startups are developing drugs that deliver a dose of radiation directly to tumors. Here’s where they stand, and why their progress is worth watching. Editor’s note: This story was published in August 2023 and, since then, the radiopharmaceuticals field has advanced quickly. We’re including this story in the trendline you’re reading as it provides a useful snapshot of when the field started to take off. When the Food and Drug Administration approved a new prostate cancer drug in
Biotech and Pharma Industry News | BioPharma Dive (opens the original)
Read excerpt
Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial. At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer
Biotech and Pharma Industry News | BioPharma Dive (opens the original)
Read excerpt
Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial. At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval (opens the original)
Read excerpt
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
FDA starts review of Roche’s multiple sclerosis pill (opens the original)
Read excerpt
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program. Fenebrutinib is among a class of drugs known as BTK, or Bruton’s tyrosine kinase, inhibitors. Earlier versions of these therapies initially came to market as cancer treatments. Newer prospects are now being tested against a range of autoimmune disorders. So far, research has produced somewhat mixed results. Novartis’ Rhapsido and Sanof
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.